Comparative Pharmacology
Head-to-head clinical analysis: AXID versus PEPCID AC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXID versus PEPCID AC.
AXID vs PEPCID AC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive, reversible inhibition of histamine at H2-receptors on gastric parietal cells, reducing gastric acid secretion by blocking the H2-receptor-mediated activation of adenylate cyclase and subsequent cAMP production.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
300 mg orally once daily at bedtime or 150 mg orally twice daily. Max 300 mg/day.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
None Documented
None Documented
1.5-2.5 hours (prolonged in renal impairment: up to 4-5 hours if CrCl <20 mL/min)
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
Renal (60% unchanged), biliary (30%), fecal (<10%)
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist